It was demonstrated that alternative activation of P38MAPK supported RAF-independent activation of the MEK/ERK pathway in the presence of sorafenib and was required to acquire sorafenib resistance in the mouse HCC model [8]. This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.